Menarini Asia-Pacific

Company snapshot

Menarini Asia-Pacific is a member of the Menarini Group, a leading international pharmaceutical and diagnostic company with a heritage of over 135 years and over 17,000 employees in 140 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people. Menarini Asia-Pacific operates across the entire commercial value chain,

• 6 approved product(s) across US/EU regulatory metadata.
• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Menarini Asia-Pacific. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Menarini Asia-Pacific.

1. Jun 8, 2026 Clinical update

   AMIL/25/Obi-Dys/001 — Phase 3

2. Jun 8, 2026 Clinical update

   Vaborem 1 g/1 g powder for concentrate for solution for infusion — Phase 2

View all clinical trial activity →

• What is Menarini Asia-Pacific?

  A.Menarini Australia Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dyslipidemia at High to Very High Cardiovascular Risk, Suspected or confirmed Gram negative infections. NovaPharmaNews links 2 clinical program(s), 5 drug profil

• Is Menarini Asia-Pacific publicly traded?

  Menarini Asia-Pacific appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Menarini Asia-Pacific develop or market?

  We link 15 drug profile(s) where Menarini Asia-Pacific is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/menarini-international-operations-luxembourg-s-a-miol#company-drugs.

• What are the latest developments for Menarini Asia-Pacific?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Menarini Asia-Pacific focus on?

  Menarini Asia-Pacific focuses on Dyslipidemia at High to Very High Cardiovascular Risk, Suspected or confirmed Gram negative infections based on our analysis of their pipeline programs and drug development activities.